Daxas: a new add-on therapy in severe COPDRoflumilast will be the first phosphodiesterase-4 (PDE4) inhibitor to be marketed in Canada. Bev Allen named 2010 Pillar of Pharmacy Award recipientJoins other distinguished award winners for his life-long commitment to the profession of pharmacy. Levothyroxine: best taken at bedtime Llevothyroxine improves thyroid hormone levels more when taken at bedtime compared to morning on empty stomach. New drugs get a rise out of HDL Phase II trials look promising, but larger outcome studies needed Opioid and diet pill bite the dust following safety concerns Best approach to oxycodone woes: Take it off the market Or, refuse to prescribe it to force drug-makers to end production Letter of concern to gov’t sparks quick ER responses In the wake of Dr. Paul Parks’ now famous e-mail outlining concern over ER overcrowding, the province has made some progress on the issue. Oakville Hospital receives $3.5-million donation Managing recurrent UTIs in women The Society of Obstetricians and Gynaecologists of Canada updates guidelines on treatment, prevention of recurrent urinary tract infections in women. Thelin (sitaxsentan): PAH drug withdrawn worldwide Pfizer Canada is voluntarily withdrawing Thelin from the market worldwide due to concerns about hepatotoxicity. First Previous 1088 1089 1090 1091 1092 Next Last
